Real-world comprehensive diagnosis and Surgery plus X treatment strategy of early-stage synchronous multiple primary lung cancer

Background Diagnosing and treating synchronous multiple primary lung cancers (sMPLC) are complex and challenging. This study aimed to report real-world data on the comprehensive diagnosis and treatment of patients with early-stage sMPLC.Materials and Methods A single-center cohort study was carried out and a large number of patients with early-stage sMPLC were included. A single- or two-stage surgery was performed to remove the primary and co-existing lesions. The X strategies, including ablation, SBRT, and EGFR-TKIs treatment, were applied to treat the high-risk residual lesions. Wide panel-genomic sequencing was performed to assess the genetic heterogeneity of the co-existing lesions.Results A total of 465 early-stage sMPLC patients with 1198 resected lesions were included. Despite most patients being histologically different or harboring different genetic alternations, about 7.5% of the patients had the same histological type and driver gene mutation changes, comprehensive re-evaluation is thus needed. The Surgery + X strategy showed remarkable efficacy and safety in treating multiple lesions. Follow-up data revealed that the T2 stage (p = 0.014) and the solid presence of a primary lesion (p < 0.001) were significantly related to tumor recurrence. And a T2-stage primary tumor had a significantly higher rate of developing new lesions after the initial surgery (p < 0.001).Conclusions In real-world practice, histopathological and radiological evaluation combined with genetic analyses could be a robust diagnostic approach for sMPLC. The Surgery + X treatment strategy showed remarkable efficacy, superiority, and safety in the clinical treatment of early-stage sMPLC.

Automated summary

This study reported real-world data on the comprehensive diagnosis and treatment of patients with early-stage synchronous multiple primary lung cancers (sMPLC). The results showed that histopathological and radiological evaluation combined with genetic analyses could be a robust diagnostic approach for sMPLC. The Surgery + X treatment strategy demonstrated remarkable efficacy, superiority, and safety in the clinical treatment of early-stage sMPLC.